Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Jan 30, 2019

SELL
$30.43 - $56.65 $106,505 - $198,275
-3,500 Closed
0 $0
Q3 2018

Nov 02, 2018

BUY
$46.46 - $68.49 $162,610 - $239,714
3,500 New
3,500 $213,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $259M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Gabelli Funds LLC Portfolio

Follow Gabelli Funds LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gabelli Funds LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gabelli Funds LLC with notifications on news.